WELL ON OUR WAY

June 27, 2018

The life sciences landscape is witnessing a dynamic transformation. With volatile political, socio-economic and scientific events clouding the spectrum there are many challenges. However, with every challenge, awaits a great opportunity at the horizon. And as the market dynamics change, Companies will need to employ innovative strategies for success. Successful implementation of these strategies requires constant re-evaluation and enhancement of processes.

Spotlight

Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, anabasum, is a novel synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Anabasum has demonstrated positive clinical data in Phase 2 studies evaluating anabasum for the treatment of diffuse cutaneous systemic sclerosis and for the treatment of cystic fibrosis. Additionally, anabasum is being evaluated in a Phase 2, 12-month open-label extension study in systemic sclerosis, a Phase 2 study in skin-predominant dermatomyositis with a 12-month open-label extension, and another Phase 2 study in systemic lupus erythematosus is scheduled to commence in H2 2017.

OTHER WHITEPAPERS
news image

Boost Your Business In Chemical Industry With Sap Commerce Cloud

whitePaper | April 21, 2023

A B2B E-Commerce platform also provides companies with access to real-time data and insights that can help to inform and guide their business decisions.

Read More
news image

THE INTELLIGENT ENTERPRISE FOR THE OIL AND GAS INDUSTRY

whitePaper | April 30, 2021

Learn SAP’s perspective on where the oil and gas industry will go and how SAP contributes to the evolution of the industry in a digital world. SAP Industries White Paper | Oil and Gas© 2021 SAP SE or an SAP affiliate company. All rights reserved. 2“In the experience economy, oil and gas companies that are intelligent enterprises embrace market standards and the cloud to innovate and differentiate.”

Read More
news image

Workflow Management Software for Chemical Manufacturing

whitePaper | March 6, 2023

Companies are adapting to the transformation of the chemical manufacturing industry by the digital world. This transformation coincides with challenges either to a specific organization, or the existing technology and resources.

Read More
news image

Chain Reaction: Conquering Labeling Challenges in the Chemical Industry

whitePaper | February 28, 2020

Reversing the complexity of global labeling management in the chemicals industry, so that intensifying regulatory demands don’t encroach on international market opportunity Trust, transparency and, above all, the safety of process/supply-chain intermediaries and consumers, is of paramount importance to the global chemicals industry. Yet, increasingly-stringent regulations about product/substance-based declarations, hazard warnings, and use of mandatory safety statements and symbols, is taking its toll on international brands.

Read More
news image

Cumulative Impacts Recommendations for ORD Research

whitePaper | January 15, 2022

This white paper was developed to inform the Office of Research and Development's (ORD) FY23-26 Strategic Research Action Plans (StRAPs) under development by the six national research programs.

Read More
news image

Petrochemical Processing

whitePaper | February 4, 2020

Outstanding process technology Together with the proven furnace technology Linde offers a separation process which is based on a unique sequence with front-end hydrogenation and open loop heat pump driven C2 splitter. These cornerstones of Linde’s technology have been developed during 60 years in cryogenic separation of ethylene from gas mixtures. The separation technology of Linde is superior to other concepts and has been applied to improve the performance even in plants of competitive technologies.

Read More

Spotlight

Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, anabasum, is a novel synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Anabasum has demonstrated positive clinical data in Phase 2 studies evaluating anabasum for the treatment of diffuse cutaneous systemic sclerosis and for the treatment of cystic fibrosis. Additionally, anabasum is being evaluated in a Phase 2, 12-month open-label extension study in systemic sclerosis, a Phase 2 study in skin-predominant dermatomyositis with a 12-month open-label extension, and another Phase 2 study in systemic lupus erythematosus is scheduled to commence in H2 2017.

Events